Prof Paul Neeson
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
260 Scholarly works
20 Projects
HIGHLIGHTS
2026
Journal article
Why CD4 T cells matter in adoptive cell therapy for solid cancers.
DOI: 10.1016/j.iotech.2026.1016152026
Journal article
Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma
DOI: 10.1038/s41467-026-74255-x2026
Journal article
Single-fraction or multi-fraction stereotactic ablative body radiotherapy followed by atezolizumab in advanced triple-negative breast cancer: a randomized phase II trial
DOI: 10.1038/s41467-026-75660-y2026
Journal article
Recurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancer
DOI: 10.1038/s41467-026-74334-z2022
Research grants (ARC, NHMRC, MRFF)
Targeting Cold Tumours With Triple Therapy
2017
Research grants (other domestic)
Novel Approaches for Overcoming Resistance to Therapies for Advanced Melanoma
2017
Research Grant
Combination of Radionuclide 177lu-Psma Therapy With Pembrolizumab in Patients With Metastatic Castration-Resistant Prostate Cancer (Mcrpc)
RECENT SCHOLARLY WORKS
2026
Journal article
Tumor-resident T cells and dendritic cells form an in situ archetype during immunotherapy response in melanoma
DOI: 10.1038/s41467-026-74076-y2026
Journal article
Tumor-Intrinsic Blood and Imaging Correlatives in Advanced Prostate Cancer Treated with Combination Radiopharmaceutical Therapy and Immunotherapy.
DOI: 10.2967/jnumed.126.2732662026
Journal article
Germline BRCA1 pathogenic variants and T cell dysfunction
DOI: 10.1016/j.iotech.2026.1016012026
Journal article
Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials
DOI: 10.1016/j.eururo.2026.03.0242026
Journal article
ENHANCING CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY FOR PAEDIATRIC SARCOMA THROUGH CAR T ENGINEERING AND TUMOUR MICROENVIRONMENT REWIRING
DOI: 10.1016/j.jcyt.2026.1022252026
Journal article
[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study
DOI: 10.1016/S1470-2045(26)00017-3
RECENT PROJECTS
2026
Research grants (other domestic)
Harnessing the Immunomodulatory Capacity of Curaxin CBL0137 to Enhance Immunotherapy for High-Risk Solid Childhood Cancers
2026
Research grants (other domestic)
First-Line Bispecific Antibody Therapy in Diffuse Large B-Cell Lymphoma: Effects on Subsequent CAR T Cell Production